Back to Search
Start Over
ATI-2307 Exhibits Equivalent Antifungal Activity in Cryptococcus neoformans Clinical Isolates With High and Low Fluconazole IC50.
- Source :
- Frontiers in Cellular & Infection Microbiology; 6/23/2021, Vol. 11, p1-6, 6p
- Publication Year :
- 2021
-
Abstract
- Half maximal inhibitory concentrations (IC<subscript>50</subscript>) to the experimental drug ATI-2307 and complete inhibition (IC<subscript>90</subscript>) of the common clinically used antifungal drug amphotericin B were determined by microbroth dilution assay for a collection of 69 clinical isolates of Cryptococcus neoformans from Uganda that had high fluconazole IC<subscript>50</subscript> values. The majority of the clinical isolates tested had fluconazole IC<subscript>50</subscript> at or above 8 µg/mL, but were susceptible to both amphotericin B (IC<subscript>90</subscript> ≤1 μg/mL) and ATI-2307 (IC50 ≤0.0312 µg/mL). No correlation between increased fluconazole minimum inhibitory concentration (MIC) and ATI-2307 or amphotericin B MIC was observed, suggesting that the cellular changes impacting fluconazole susceptibility did not impact the effectiveness of ATI-2307. Our results suggest that ATI-2307 is a promising new antifungal drug for use in the context of high fluconazole or other antifungal drug MICs and/or in combination drug therapy regimens. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 22352988
- Volume :
- 11
- Database :
- Complementary Index
- Journal :
- Frontiers in Cellular & Infection Microbiology
- Publication Type :
- Academic Journal
- Accession number :
- 151041448
- Full Text :
- https://doi.org/10.3389/fcimb.2021.695240